Pfizer has updated the labeling for Exubera (insulin human [rDNA original]) inhalation powder to include a warning about lung cancer cases observed in patients who used Exubera. This update is based on a review of clinical trial data which showed more Exubera-treated patients (6 of 4,740) developed lung cancer compared to patients not treated with Exubera (1 of 4,292). One case of lung cancer was also reported in an Exubera post-marketing report. Although there are too few cases to determine whether the development of lung cancer is related to Exubera, all patients who developed lung cancer had a prior history of cigarette smoking.
Exubera is an inhalable short-acting insulin that helps to control glucose in adults with diabetes.
For more information call (800) EXUBERA or visit www.exubera.com.